Metamizole as pain treatment in patients with chronic pancreatitis, a multicenter, randomized, double-blind, placebo-controlled trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504143-14-00

Enrollment

Registered

2023-10-11

Start date

2024-05-02

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pancreatitis

Brief summary

Mean daily pain intensity score, recorded during the 4-week intervention by the patient using a 11-point numerical rating (0 = no pain to 10 = worst pain imaginable)

Detailed description

Izbicki pain score, COMPAT-SF, mean of maximum daily pain intensity score, number of patients achieving successful pain reduction, number of pain free days, number of days with acceptable pain, total amount of milligrams morphine equivalent (MME) and MME required as escape medication, QoL (PANQOLI and SF-36), patient satisfaction (PGIC), side effects

Interventions

DRUGPlacebo metamizole sodium monohydrate 500 mg film-coated tablet

DRUGDolamizol 500 mg tablet

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean daily pain intensity score, recorded during the 4-week intervention by the patient using a 11-point numerical rating (0 = no pain to 10 = worst pain imaginable)	—

Secondary

Measure	Time frame
Izbicki pain score, COMPAT-SF, mean of maximum daily pain intensity score, number of patients achieving successful pain reduction, number of pain free days, number of days with acceptable pain, total amount of milligrams morphine equivalent (MME) and MME required as escape medication, QoL (PANQOLI and SF-36), patient satisfaction (PGIC), side effects	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026